Rivastigmine and Tolterodine Interaction

Drug interaction information between Rivastigmine and Tolterodine.

Rivastigmine and Tolterodine have a documented minor interaction in FDA labeling.

FDA drug labeling documents a minor-severity interaction between Rivastigmine and Tolterodine. This page displays the available source-record category and label text. The category is not an individual risk estimate or medication-combination direction.

Drug A

Rivastigmine

Acetylcholinesterase Inhibitor

Drug B

Tolterodine

Anticholinergic (Overactive Bladder)

How They Interact

Rivastigmine works against drugs like tolterodine. This means tolterodine might not work as well when taken with rivastigmine.

FDA Label Information

7.2 Cholinomimetic and Anticholinergic Medications Rivastigmine tartrate may increase the cholinergic effects of other cholinomimetic medications and may also interfere with the activity of anticholinergic medications (e.g., oxybutynin, tolterodine).

Frequently Asked Questions

What SPL severity band is on file for Rivastigmine + Tolterodine?

Compiled FDA labeling labels this pair minor. That is a source-record field, not an individual medication-combination decision.

Which drug in this pair has the larger labeled-interaction portfolio?

Tolterodine has 15 labeled pairs on file vs Rivastigmine's 4. In the minor band specifically: Rivastigmine has 3 (also Atenolol, Oxybutynin); Tolterodine has 14 (also Omeprazole, Hydrochlorothiazide, Fluoxetine, Furosemide).

What mechanism field is on file for Rivastigmine and Tolterodine?

Rivastigmine works against drugs like tolterodine. This means tolterodine might not work as well when taken with rivastigmine.

Tolterodine's labeled portfolio outnumbers Rivastigmine

SPL source-record counts only. This page's band is minor · classes on file: Rivastigmine (Acetylcholinesterase Inhibitor); Tolterodine (Anticholinergic (Overactive Bladder)).

Rivastigmine

0 major · 1 moderate · 3 minor · 4 total

Tolterodine

0 major · 1 moderate · 14 minor · 15 total

Sources: FDA Drug Labels (SPL) via openFDA (2026). This is for informational purposes only and is not medical advice. This registry does not provide individual medication-combination directions.